Overall, the presented data showed that ATRi significantly (P<0.05) potentiates the synthetic lethality effect of ARID1B knock-down in ARID1A deficient CRC cell lines (Supplemental Figure S5; Supplemental Table S2). The gene discussed is ARID1B; the disease is colorectal carcinoma.